Skip to content
Search

Latest Stories

RPS urges pharmacy to join in its commitment to tackling climate emergency

The Royal Pharmaceutical Society has called on pharmacy to commit to sustainability as it pledges to become a truly environmentally responsible organisation.

"The climate crisis is the biggest threat modern society has ever faced," the RPS said in statement on Wednesday (September 1).


That’s why its "three national boards and Assembly have made a climate change declaration and are committing to collaborate with governments and other bodies across the world to tackle this crisis."

To accompany its declaration, the RPS said it was making "a series of proactive commitments to influence change and hold ourselves accountable" which would include developing pharmacy’s role in decarbonisation -- focusing on areas such as public health and prevention of disease, the medicines supply chain and the infrastructure in which pharmacy teams work.

The RPS will also work with various governments, health services and the pharmaceutical industry to "deliver on their sustainability strategies" and advocate how the entire pharmacy profession can contribute.

Claiming that it was "already a zero to landfill organisation" which champions recycling and eliminating single use plastics on its sites, the RPS says it will convert to 100 per cent renewable energy across its offices in Cardiff, Edinburgh and London and reduce our overall energy and water usage.

RPS president Professor Claire Anderson said: “The climate crisis will not just have an impact on the pharmacy profession, but your family, friends, and everyday life.

“The RPS declaration is leading the way for pharmacy and demonstrates our commitment to change.

“It’s more important than ever that we turn words into action and become more sustainable and this applies to everyone. As individual practitioners and collectively as a profession, we must identify where we can make changes in our practice to reduce carbon emissions.

“Join us by acting now, and change the direction we are going in.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less